Source: yahoo_news
Source ID: yahoo:962e5adaefe96dc86168d4b470afc513:PALI
URL: https://finance.yahoo.com/healthcare/articles/palisade-bio-receives-fda-clearance-123500613.html?.tsrc=rss
Symbol: (PALI)
Published: 2026-09-22 08:35:00 EDT
Time precision: minute
Title: Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD

Palisade Bio, Inc. Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn’s disease (CD) ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic acti